Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin’s lymphoma in vitroMarion Masitsa Malenge, Jostein Dahle, Ada H. V. Repetto‐Llamazares et al.|PLoS ONE|2022Cited by 3